Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-45. (canceled)

46. (New) A compound having the formula



and its N-oxide forms, pharmaceutically acceptable addition salts and stereo-chemically isomeric forms, wherein

n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

with the proviso that both n and m cannot be 0;

R^1 represents hydrogen, Ar^1, C_{1-4}alkyl or C_{1-4}alkyl substituted with morpholinyl or pyridinyl;

R^2 and R^3 taken together with the carbon atom to which they are attached form a

C_{3-8}cycloalkyl or Het^1 wherein said C_{3-8}cycloalkyl or Het^1 each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from C_{1-4}alkyloxycarbonyl, -C_{1-4}alkyl-Ar^3

C_{1-4}alkylsulfonyl, aminosulfonyl, mono- or di(C_{1-4}alkyl)aminosulfonyl or –C(=NH)-NH_2;

R^4 represents halo, nitro , hydroxy or C_{1-4}alkyloxy;

R^5 represents formyl, hydroxy, cyano, phenyl, -O-Ar^2, NR^6R^7, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl), Het^2, -SO_2-Het^6, C_{2-6}alkenyl optionally substituted with phenyl,

C_{1-4}alkyl substituted with one or where possible more substituent being selected from hydroxy, halo, Het^3, NR^6R^7 or formyl,

C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from halo, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, aminosulfonyl, Het^4, NR^8R^9 or -C(=O)-Het^4;

R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy, Het^5, C_{1-4}alkyloxycarbonyl, or C_{1-4}alkylsulfonyl;

R^8 and R^9 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, Het^7, mono- or di(C_{1-4}alkyl)aminosulphonyl or aminosulphonyl;

Het^1 represents piperidinyl or dihydroindenyl;

Het^2 represents a heterocycle selected from piperidinyl, morpholinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C_{1-4}alkyloxycarbonyl;

Het^3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, pyrrolyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, hydroxyC_{1-4}alkyl, aminosulfonyl, $NR^{10}R^{11}$, imidazolyl, tetrahydropyrimidinyl, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy;

R^{10} and R^{11} are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, aminosulfonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^4 represents a heterocycle selected from morpholinyl, piperidinyl, imidazolyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, aminosulfonyl or mono- or di(C_{1-4}alkyl)aminosulfonyl or Het^4 represents a monovalent radical represented by formula (i);



(i)

Het^5 represents a heterocycle selected from pyridinyl, pyrimidinyl, pyrrolidinyl, or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, aminosulfonyl, C_{1-4}alkylaminosulfonyl or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^6 represents morpholinyl;

Het^7 represents pyridinyl, piperidinyl, piperazinyl or pyrimidinyl optionally substituted with C_{1-4}alkylphenyl, C_{1-4}alkyloxycarbonyl aminosulfonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Ar^1 represents an aryl substituent selected from phenyl or naphthalenyl wherein said aryl substituents each independently may optionally be substituted with one, or where possibly two or three substituents each independently selected from nitro or C_{1-4}alkyloxycarbonyl;

Ar^2 represents phenyl optionally substituted with one or where possible two or three substituents each independently selected from the group consisting of halo and nitro;

Ar^3represents an aryl substituent selected from the group consisting of phenyl,

47. (New) A compound according to claim 46 wherein;

R^1 represents Ar^1, C_{1-4}alkyl, or C_{1-4}alkyl substituted with morpholinyl;

R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl or Het^1 wherein said C_{3-8}cycloalkyl or Het^1 each independently may optionally be substituted with C_{1-4}alkyloxycarbonyl;

R^4 represents halo or R^4 represents C_{1-4}alkyloxy;

R^5 represents C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl), C_{1-4}alkyl substituted with one or where possible more substituent being selected from Het^3 or NR^6R^7,

C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from amino, Het^4 or NR^8R^9;

R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy or Het^5;

R^8 and R^9 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, Het^7 or mono- or di(C_{1-4}alkyl)aminosulphonyl;

Het^1 represents piperidinyl;

Het^3 represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C_{1-4}alkyl, aminosulfonyl, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy;

Het^5 represents pyridinyl optionally substituted with mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^7 represents piperidinyl optionally substituted with C_{1-4}alkylphenyl, C_{1-4}alkyloxycarbonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Ar^1 represents an aryl substituent selected from phenyl or naphthalenyl;

48. (New) A compound according to claim 46 wherein;

R^1 represents C_{1-4}alkyl;

R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl or piperidinyl wherein said C_{3-8}cycloalkyl or Het^1 each independently may optionally be substituted with C_{1-4}alkyloxycarbonyl;

R^4 represents halo or C_{1-4}alkyloxy;

R^5 represents C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl), C_{1-4}alkyl substituted with one or where possible more substituent being selected from Het^3 or NR^6R^7,

C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from amino, Het^4 or NR^8R^9;

R^6 and R^7 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, -Het^5 or C_{1-4}alkyl substituted with one or where possible more substituents being selected from hydroxy, or Het^5;

R^8 and R^9 are each independently selected from hydrogen, C_{1-4}alkyl, -Het^7 or mono- or di(C_{1-4}alkyl)aminosulphonyl;

Het^3 represents a heterocycle selected from piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, aminosulfonyl, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkyl or C_{1-4}alkyloxy;

Het^4 represents a heterocycle selected from morpholinyl, piperidinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^5 represents a heterocycle selected from pyridinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, or mono- or di(C_{1-4}alkyl)aminosulfonyl;

Het^7 represents piperidinyl.

49. (New) A compound as claimed in claim 46, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl.

50. (New) A compound as claimed in claim 49, wherein R^2 and R^3 taken together with the carbon atom to which they are attached are cyclopentyl.

51. (New) A compound according to claim 46 wherein R^5 represents formyl, hydroxy, cyano, phenyl, -O-Ar^2, NR^6R^7, C_{1-4}alkylsulfonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonyl, -O-(mono- or di(C_{1-4}alkyl)aminosulfonyl), Het^2, -SO_2-Het^6, C_{2-6}alkenyl optionally substituted with phenyl,
C_{1-4}alkyl substituted with one or where possible more substituent being selected from hydroxy, halo, Het^3, NR^6R^7 or formyl, or
C_{1-4}alkyloxy substituted with one or where possible more substituents being selected from halo, amino, mono- or di(C_{1-4}alkyl)aminosulfonyl, aminosulfonyl, Het^4, NR^8R^9 or -C(=O)-Het^4;

52. (New) A compound according to claim 46, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents C_{1-4}alkylsulfonyl or C_{1-4}alkylcarbonyl,

53. (New) A compound according to claim 52, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylsulfonyl or methylcarbonyl.

54. (New) A compound as claimed in claim 46, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C_{1-4}alkyl substituent,
or Het^4 consists of piperazinyl substituted with one mono- or di(C_{1-4}alkyl)aminosulfonyl substituent.

55. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in claim 46.

56. (New) A process of preparing a compound as described in claim 46, comprising

i) reacting a primary amine of formula (V) with an aldehyde of formula (VI) in a condensation reaction using ethanol as a suitable solvent;



e) EtOH

ii) followed by a nitrosative cyclisation of the thus obtained Schiffs bases of formula (II) with $NaNO_2$ in acetic acid, and refluxing the nitroso intermediates of formula (III) in a suitable solvent such as acetic anhydride or ethanol further comprising dithiothreitol (DTT);



a) $NaNO_2$, AcOH, H_2O b) DTT, EtOH

57. (New) A compound as claimed claim 46, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form a C_{3-8}cycloalkyl.

58. (New) A compound as claimed claim 57, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form cyclopentyl.

59. (New) A compound according to claim 46, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents C_{1-4}alkylsulfonyl or C_{1-4}alkylcarbonyl.

60. (New) A compound according to claim 59, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylsulfonyl or methylcarbonyl.

61. (New) A compound according to claim 60, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylsulfonyl.

62. (New) A compound according to claim 60, provided that when R^5 represents NR^6R^7, either R^6 or R^7 represents methylcarbonyl.

63. (New) A compound as claimed in claim 46, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C_{1-4}alkyl substituent, or Het^4 consists of piperazinyl substituted with one mono- or di(C_{1-4}alkyl)aminosulfonyl substituent.

64. (New) A compound as claimed in claim 63, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

65. (New) A compound as claimed in claim 47, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with

dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

66. (New) A compound as claimed in claim 48, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R^5 substituent.

67. (New) A compound as claimed in claim 50, provided that when R^5 represents a C_{1-4}alkyloxy substituted Het^4, said Het^4 being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R^5 substituent, or Het^4 consists of piperazinyl substituted with dimethylaminosulfonyl, in the para position relative to the carbon atom bearing the R^5 substituent.